2018年2月26日 · Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management...

2014年7月24日 · For almost 10 years, the main goal of the treatment of CML with tyrosine kinase inhibitors (TKIs) has been the achievement of the so-called “major molecular response” (MMR; BCR-ABL1 ≤ 0.1% on the International Scale) 2 (see figure).

2018年11月30日 · Quantitative PCR assays of peripheral blood, measuring the level of BCR-ABL1 messenger RNA relative to an internal control gene, are the gold standard for monitoring in chronic myeloid leukemia (CML), with the degree of leukemic cell burden translating to critically important prognostic information.

2020年3月3日 · Achieving an MMR (BCR-ABL1 ≤ 0.1%) predicts a CML-specific survival close to 100% as disease progression is uncommon once this level of cytoreduction has been achieved.

Since the introduction of the drug Gleevec® and similar tyrosine kinase inhibitors, the number of patients with chronic myeloid leukemia (CML) who enter remission and stay in remission for years has increased dramatically over the past decade. For survival statistics, click here.

2023年4月24日 · In this review, we discuss these issues to clarify questions about the management of CML in frontline and post-frontline TKI failure settings. The primary aim of CML therapy is to improve...

A major molecular response (MMR) means that the amount of BCR-ABL gene in your blood or bone marrow is 1/1000 th (or less) of what's expected in someone with untreated CML. You may hear the terms long-term deep molecular response or durable complete molecular response .

2012年3月3日 · Chronic myeloid leukemia (CML) affects 1 to 2 people per 100,000 annually, with an estimated 5,000 patients diagnosed in the United States each year (Altekruse et al., 2009). The underlying cause of CML is a translocation between chromosomes 9 and 22 that results in an abnormal chromosome known as the Philadelphia (Ph) chromosome.

2012年11月16日 · In order to describe the different treatments and factors involved in the first major molecular response (MMR) occurence in chronic phase CML, its maintenance, and its conversion to complete molecular response (CMR), we analyzed 211 CML patients [124 males and 87 females; median age: 50 years (17–81)] in first chronic phase who received ...

Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML …